A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
Study Details
Study Description
Brief Summary
The primary purpose of this study is to investigate the effectiveness reflected by the retention rate of perampanel as the only add-on treatment in adult participants with primary generalized tonic-clonic (PGTC) or secondarily generalized tonic-clonic (SGTC) seizures based on focal or idiopathic generalized epilepsy in a non-interventional (observational) setting.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Perampanel Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit). |
Drug: Perampanel
Perampanel tablets.
Other Names:
Drug: Perampanel
Perampanel oral suspension.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants Remaining on Perampanel at Month 12 (Retention Rate) [Month 12]
The retention rate is defined as the percentage of participants remaining on perampanel treatment at 12 months after the initiation of treatment.
Secondary Outcome Measures
- Percentage of Participants Remaining on Perampanel at Month 6 (Retention Rate) [Month 6]
The retention rate is defined as the percentage of participants remaining on perampanel treatment at 6 months after the initiation of treatment.
- Percentage of Participants Who Achieved Seizure Freedom for All Generalized Tonic-clonic (GTC) Seizures at Month 12 [Month 12]
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Treatment-emergent Serious Adverse Events (SAE), and Adverse Events (AEs) by Severity [Up to Month 12]
AEs will be graded on a 3-point scale that is mild (discomfort noticed, but no disruption of normal daily activity), moderate (discomfort sufficient to reduce or affect normal daily activity), and severe (incapacitating, with inability to work or to perform normal daily activity).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed diagnosis of epilepsy with PGTC or SGTC seizures based on focal or idiopathic generalized epilepsy
-
Active epilepsy with GTC seizures, demonstrated by the occurrence of at least 1 GTC seizure within 3 months before inclusion
-
The decision to prescribe perampanel was made by the physician before and irrespective of his/her decision to include the participant in the study
-
Receiving treatment with perampanel in line with the current Fycompa (perampanel) SmPC
-
Perampanel must either be newly administered as the only add-on treatment to a current antiepileptic drug (AED) monotherapy or must be planned to substitute one of two AEDs of a current dual therapy planned to be stopped within 2 months after initiation of treatment with perampanel. It will be specified which AED is planned to be substituted by perampanel upon inclusion. It is assumed that participants start treatment with perampanel closely after the baseline visit. Retrospective inclusions will be allowed, but only if the time between the initiation of perampanel treatment and inclusion does not exceed 7 calendar days. In this case, the baseline visit documentation should reflect the situation (including seizure situation 3 months before baseline and baseline medication) to the date perampanel treatment was initiated
Exclusion Criteria:
-
Participants with known psychogenic non-epileptic seizures
-
The participant had already received perampanel in the past
-
Simultaneous participation in an interventional clinical study and/or taking an investigational drug
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Eisai Trial Site #51 | Aalen | Germany | ||
| 2 | Eisai Trial Site #12 | Berlin | Germany | ||
| 3 | Eisai Trial Site #43 | Berlin | Germany | ||
| 4 | Eisai Trial Site #15 | Bernau | Germany | ||
| 5 | Eisai Trial Site #8 | Bielefeld | Germany | ||
| 6 | Eisai Trial Site #53 | Bochum | Germany | ||
| 7 | Eisai Trial Site #38 | Bonn | Germany | ||
| 8 | Eisai Trial Site #9 | Bonn | Germany | ||
| 9 | Eisai Trial Site #25 | Damp | Germany | ||
| 10 | Eisai Trial Site #48 | Dortmund | Germany | ||
| 11 | Eisai Trial Site #27 | Dresden | Germany | ||
| 12 | Eisai Trial Site #50 | Dresden | Germany | ||
| 13 | Eisai Trial Site #7 | Erlangen | Germany | ||
| 14 | Eisai Trial Site #44 | Friedrichshafen | Germany | ||
| 15 | Eisai Trial Site #4 | Greifswald | Germany | ||
| 16 | Eisai Trial Site #21 | Hamburg | Germany | ||
| 17 | Eisai Trial Site #47 | Hamburg | Germany | ||
| 18 | Eisai Trial Site #14 | Jena | Germany | ||
| 19 | Eisai Trial Site #18 | Kiel | Germany | ||
| 20 | Eisai Trial Site #54 | Kiel | Germany | ||
| 21 | Eisai Trial Site #1 | Kork | Germany | ||
| 22 | Eisai Trial Site #24 | Leipzig | Germany | ||
| 23 | Eisai Trial Site #28 | Lübeck | Germany | ||
| 24 | Eisai Trial Site #26 | Magdeburg | Germany | ||
| 25 | Eisai Trial Site #13 | Mainz | Germany | ||
| 26 | Eisai Trial Site #36 | Mittweida | Germany | ||
| 27 | Eisai Trial Site #42 | Nierstein | Germany | ||
| 28 | Eisai Trial Site #2 | Radeberg | Germany | ||
| 29 | Eisai Trial Site #16 | Ravensburg | Germany | ||
| 30 | Eisai Trial Site #23 | Regensburg | Germany | ||
| 31 | Eisai Trial Site #46 | Remscheid | Germany | ||
| 32 | Eisai Trial Site #3 | Tübingen | Germany | ||
| 33 | Eisai Trial Site #37 | Ulm | Germany | ||
| 34 | Eisai Trial Site #40 | Weil der Stadt | Germany |
Sponsors and Collaborators
- Eisai GmbH
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- E2007-M049-509